TY - JOUR T1 - Fever, Diarrhea, and Severe Disease Correlate with High Persistent Antibody Levels against SARS-CoV-2 JF - medRxiv DO - 10.1101/2021.01.05.21249240 SP - 2021.01.05.21249240 AU - Maya F. Amjadi AU - Sarah E. O’Connell AU - Tammy Armbrust AU - Aisha M. Mergaert AU - Sandeep R. Narpala AU - Peter J. Halfmann AU - S. Janna Bashar AU - Christopher R. Glover AU - Anna S. Heffron AU - Alison Taylor AU - Britta Flach AU - David H. O’Connor AU - Yoshihiro Kawaoka AU - Adrian B. McDermott AU - Ajay K. Sethi AU - Miriam A. Shelef Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/06/2021.01.05.21249240.abstract N2 - Lasting immunity will be critical for overcoming the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, factors that drive the development of high titers of anti-SARS-CoV-2 antibodies and how long those antibodies persist remain unclear. Our objective was to comprehensively evaluate anti-SARS-CoV-2 antibodies in a clinically diverse COVID-19 convalescent cohort at defined time points to determine if anti-SARS-CoV-2 antibodies persist and to identify clinical and demographic factors that correlate with high titers. Using a novel multiplex assay to quantify IgG against four SARS-CoV-2 antigens, a receptor binding domain-angiotensin converting enzyme 2 inhibition assay, and a SARS-CoV-2 neutralization assay, we found that 98% of COVID-19 convalescent subjects had anti-SARS-CoV-2 antibodies five weeks after symptom resolution (n=113). Further, antibody levels did not decline three months after symptom resolution (n=79). As expected, greater disease severity, older age, male sex, obesity, and higher Charlson Comorbidity Index score correlated with increased anti-SARS-CoV-2 antibody levels. We demonstrated for the first time that COVID-19 symptoms, namely fever, abdominal pain, diarrhea and low appetite, correlated consistently with higher anti-SARS-CoV-2 antibody levels. Our results provide new insights into the development and persistence of anti-SARS-CoV-2 antibodies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded through a COVID-19 Response grant from the Wisconsin Partnership Program and a pilot award from the Department of Medicine both at the University of Wisconsin School of Medicine and Public Health to M.A.S. Additional support was provided by the National Institutes of Health National Institute on Aging to M.F.A. (T32 AG000213), National Heart, Lung, and Blood Institute (T32 HL007899) to A.M.M., and National Institute of Allergy and Infectious Disease to A.S.H. (T32 AI007414).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human studies were performed according to the Declaration of Helsinki and were approved by the Institutional Review Board at the UW-Madison. Written informed consent was received from participants prior to inclusion in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be provided upon reasonable request. ER -